Navigation Links
Chemotherapy timing is key to success
Date:5/8/2014

>

Erlotinib, which targets a protein called the epidermal growth factor (EGF) receptor, found on tumor cell surfaces, has been approved by the Food and Drug Administration to treat pancreatic cancer and some types of lung cancer. Doxorubicin is used to treat many cancers, including leukemia, lymphoma, and bladder, breast, lung, and ovarian tumors.

Staggering these drugs proved particularly powerful against a type of breast cancer cell known as triple-negative, which doesn't have overactive estrogen, progesterone, or HER2 receptors. Triple-negative tumors, which account for about 16 percent of breast cancer cases, are much more aggressive than other types and tend to strike younger women.

That was an exciting finding, Yaffe says. "The problem was," he adds, "how do you translate that into something you can actually give a cancer patient?"

From lab result to drug delivery

To approach this problem, Yaffe teamed up with Hammond, a chemical engineer who has previously designed several types of nanoparticles that can carry two drugs at once. For this project, Hammond and her graduate student, Stephen Morton, devised dozens of candidate particles. The most effective were a type of particle called liposomes spherical droplets surrounded by a fatty outer shell.

The MIT team designed their liposomes to carry doxorubicin inside the particle's core, with erlotinib embedded in the outer layer. The particles are coated with a polymer called PEG, which protects them from being broken down in the body or filtered out by the liver and kidneys. Another tag, folate, helps direct the particles to tumor cells, which express high quantities of folate receptors.

Once the particles reach a tumor and are taken up by cells, the particles start to break down. Erlotinib, carried in the outer shell, is released first, but doxorubicin release is delayed and takes more time to seep into cells, giving erlotinib time to weaken the c
'/>"/>

Contact: Andrew Carleen
acarleen@mit.edu
617-253-1682
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Harmless human virus may be able to boost the effects of chemotherapy
2. Nanobubbles plus chemotherapy equals single-cell cancer targeting
3. New biomarker for common lung cancer predicts responses to chemotherapy
4. Scientists uncover strategy able to dramatically reduce chemotherapys side effects
5. Neutrons help explain why antibiotics prescribed for chemotherapy cause kidney failure
6. New way to kill lymphoma without chemotherapy
7. Changes to DNA on-off switches affect cells ability to repair breaks, respond to chemotherapy
8. Discovery may help prevent chemotherapy-induced anemia
9. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
10. Neuroblastoma: Autophagy protects from chemotherapy
11. Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Research and Markets ... addition of the "The Global Watermarking ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... overview of the global digital media watermarking ... and monitor piracy by securely and invisibly ...
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... sodium-retaining hormone in African Americans known to potentially cause ... of a study in the September issue of Experimental ... Temple Universitys College of Health Professions. The hormone, ... too much of it can contribute to the development ...
... may hold vital clues about how pancreatic cancer and diabetes ... access journal BMC Medicine, women with a history of gestational ... in life. The research team drawn from the US ... 37,000 mothers who gave birth between 1964 and 1976 in ...
... for our new disease problems, a far more cost ... in the places where they often commingle: in wildlife ... from the Wildlife Conservation Society (WCS) and the United ... issue of the prestigious Journal of Wildlife Diseases. ...
Cached Biology News:Understanding hypertension in African Americans proves elusive 2Emerging (disease) markets 2
(Date:12/22/2014)... Memphis, TENN (PRWEB) December 22, 2014 ... with Donor Egg Bank USA , a network ... the country. Through this partnership, patients have fast access ... for in vitro fertilization, IVF . Fertility Associates of ... to offer this fertility treatment option. , Dr. ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
Breaking Biology Technology:Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... for functional food partners and market entrance, ... Neptune Technologies &,Bioressources Inc. ("Neptune") (NASDAQ.NEPT - ... has been determined to be,safe as a ... for the,commercialization of NKO(R) incorporated into different ...
... after biological olfaction, the challenge has been to generate ... complexity to detect odors in the real world. A ... with exact chemical precision and reproducibility. , In a ... PLoS Biology, Joel White, Mary AtKisson, John Kauer and ...
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), a ... discussing its,financial results for the fourth quarter and year ended December ... 2008 at 11:00 AM ET (8:00 ... Dial information is as follows: ...
Cached Biology Technology:Neptune Technologies receives GRAS notification in the United States 2Neptune Technologies receives GRAS notification in the United States 3Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast 2
...
Request Info...
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
The FliTrx Panning Kit is designed to simplify panning for protein-protein interactions with the FliTrx Random Peptide Display Library or the pFliTrx Peptide Display Vector....
Biology Products: